Treatment Modalities for Patients with Gambling Disorder

Overview

Journal Ann Gen Psychiatry

Publisher Biomed Central

Specialty Psychiatry

Date 2017 May 4

PMID 28465711

Citations 11

Authors

Sam-Wook Choi

Young-Chul Shin

Dai-Jin Kim

Jung-Seok Choi

Seohee Kim

Seung-Hyun Kim

HyunChul Youn

Affiliations

Soon will be listed here.

Abstract

Background: Gambling disorder (GD) is defined as persistent and recurrent problematic gambling behavior leading to clinically significant impairment or distress. The prevalence of GD has been shown to be 1.2-7.1% in the general population. GD can severely impact on personal and vocational wellbeing as well as lead to financial problems, and has been known to be difficult to treat. This review describes the available pharmacotherapy/psychosocial treatments for GD patients, and summarizes data on the effectiveness of these GD treatments.

Methods: This review refers to newly as well as previously published studies and guidelines.

Results: The description of pharmacotherapy mainly focuses on opioid receptor antagonists, selective serotonin reuptake inhibitors, and mood stabilizers. Psychosocial treatments/strategies mainly include cognitive behavioral therapy, motivational interviewing, and Gamblers Anonymous. We also introduce relatively novel treatment modalities.

Conclusions: This review can help clinicians to decide treatment plans for their GD patients. In addition, it can be used as a reference for designing future research.

Citing Articles

Effectiveness of Physiotherapy in Managing Symptomatology in Gambling Disorder Patients: A Systematic Review.

Carrascosa-Arteaga P, Lopez-Liria R, Catalan-Matamoros D, Rocamora-Perez P Healthcare (Basel). 2023; 11(14).

PMID: 37510495 PMC: 10379321. DOI: 10.3390/healthcare11142055.

Are there clinical, psychopathological and therapy outcomes correlates associated with self-exclusion from gambling?.

Uriszar J, Gaspar-Perez A, Granero R, Munguia L, Lara-Huallipe M, Mora-Maltas B J Behav Addict. 2023; 12(2):522-534.

PMID: 37243745 PMC: 10316157. DOI: 10.1556/2006.2023.00018.

Serotonergic and dopaminergic control of impulsivity in gambling disorder.

Kaasinen V, Honkanen E, Lindholm K, Jaakkola E, Majuri J, Parkkola R Addict Biol. 2023; 28(2):e13264.

PMID: 36692875 PMC: 10078603. DOI: 10.1111/adb.13264.

Client's Experiences Using a Location-Based Technology ICT System during Gambling Treatments' Crucial Components: A Qualitative Study.

Diaz-Sanahuja L, Miralles I, Granell C, Mira A, Gonzalez-Perez A, Casteleyn S Int J Environ Res Public Health. 2022; 19(7).

PMID: 35409450 PMC: 8997771. DOI: 10.3390/ijerph19073769.

A Literature Review on the Efficacy and Related Neural Effects of Pharmacological and Psychosocial Treatments in Individuals With Internet Gaming Disorder.

Seo E, Yang H, Kim S, Park S, Lee S, Yoon H Psychiatry Investig. 2021; 18(12):1149-1163.

PMID: 34872237 PMC: 8721297. DOI: 10.30773/pi.2021.0207.

References

Cowlishaw S, Merkouris S, Dowling N, Anderson C, Jackson A, Thomas S . Psychological therapies for pathological and problem gambling. Cochrane Database Syst Rev. 2012; 11:CD008937. DOI: 10.1002/14651858.CD008937.pub2. View

Black D, Arndt S, Coryell W, Argo T, Forbush K, Shaw M . Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacol. 2007; 27(2):143-50. DOI: 10.1097/01.jcp.0000264985.25109.25. View

Petry N, Weinstock J, Ledgerwood D, Morasco B . A randomized trial of brief interventions for problem and pathological gamblers. J Consult Clin Psychol. 2008; 76(2):318-28. PMC: 2738749. DOI: 10.1037/0022-006X.76.2.318. View

Dannon P, Lowengrub K, Musin E, Gonopolsky Y, Kotler M . 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J Clin Psychopharmacol. 2007; 27(6):620-4. DOI: 10.1097/jcp.0b013e31815a4400. View

Zack M, Poulos C . Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. J Psychopharmacol. 2008; 23(6):660-71. DOI: 10.1177/0269881108091072. View

Black D, Shaw M, Forbush K, Allen J . An open-label trial of escitalopram in the treatment of pathological gambling. Clin Neuropharmacol. 2007; 30(4):206-12. DOI: 10.1097/wnf.0b013e31803d357f. View

Cunningham J, Hodgins D, Bennett K, Bennett A, Talevski M, Mackenzie C . Online interventions for problem gamblers with and without co-occurring mental health symptoms: Protocol for a randomized controlled trial. BMC Public Health. 2016; 16:624. PMC: 4957312. DOI: 10.1186/s12889-016-3291-7. View

Yip S, Potenza M . Treatment of Gambling Disorders. Curr Treat Options Psychiatry. 2014; 1(2):189-203. PMC: 4041397. DOI: 10.1007/s40501-014-0014-5. View

Marceaux J, Melville C . Twelve-step facilitated versus mapping-enhanced cognitive-behavioral therapy for pathological gambling: a controlled study. J Gambl Stud. 2010; 27(1):171-90. DOI: 10.1007/s10899-010-9196-y. View

10.

Benarous X, Edel Y, Consoli A, Brunelle J, Etter J, Cohen D . Ecological Momentary Assessment and Smartphone Application Intervention in Adolescents with Substance Use and Comorbid Severe Psychiatric Disorders: Study Protocol. Front Psychiatry. 2016; 7:157. PMC: 5028912. DOI: 10.3389/fpsyt.2016.00157. View

11.

Lorains F, Cowlishaw S, Thomas S . Prevalence of comorbid disorders in problem and pathological gambling: systematic review and meta-analysis of population surveys. Addiction. 2011; 106(3):490-8. DOI: 10.1111/j.1360-0443.2010.03300.x. View

12.

Larimer M, Neighbors C, Lostutter T, Whiteside U, Cronce J, Kaysen D . Brief motivational feedback and cognitive behavioral interventions for prevention of disordered gambling: a randomized clinical trial. Addiction. 2011; 107(6):1148-58. PMC: 3528181. DOI: 10.1111/j.1360-0443.2011.03776.x. View

13.

Parhami I, Siani A, Rosenthal R, Fong T . Pathological gambling, problem gambling and sleep complaints: an analysis of the National Comorbidity Survey: Replication (NCS-R). J Gambl Stud. 2012; 29(2):241-53. PMC: 3395730. DOI: 10.1007/s10899-012-9299-8. View

14.

Bowden-Jones H, Clark L . Pathological gambling: a neurobiological and clinical update. Br J Psychiatry. 2011; 199(2):87-9. DOI: 10.1192/bjp.bp.110.088146. View

15.

Hollander E, DeCaria C, Finkell J, Begaz T, Wong C, Cartwright C . A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry. 2000; 47(9):813-7. DOI: 10.1016/s0006-3223(00)00241-9. View

16.

Kim S, Grant J, Adson D, Shin Y, Zaninelli R . A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002; 63(6):501-7. DOI: 10.4088/jcp.v63n0606. View

17.

Ekholm O, Eiberg S, Davidsen M, Holst M, Larsen C, Juel K . The prevalence of problem gambling in Denmark in 2005 and 2010: a sociodemographic and socioeconomic characterization. J Gambl Stud. 2012; 30(1):1-10. DOI: 10.1007/s10899-012-9347-4. View

18.

Zack M, Poulos C . A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neuropsychopharmacology. 2007; 32(8):1678-86. DOI: 10.1038/sj.npp.1301295. View

19.

de Brito A, de Almeida Pinto M, Bronstein G, Carneiro E, Faertes D, Fukugawa V . Topiramate Combined with Cognitive Restructuring for the Treatment of Gambling Disorder: A Two-Center, Randomized, Double-Blind Clinical Trial. J Gambl Stud. 2016; 33(1):249-263. DOI: 10.1007/s10899-016-9620-z. View

20.

Rash C, Petry N . Psychological treatments for gambling disorder. Psychol Res Behav Manag. 2014; 7:285-95. PMC: 4199649. DOI: 10.2147/PRBM.S40883. View